Adebrelimab with Chemoradiotherapy for Advanced Cervical Cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is testing a new immunotherapy drug (adebrelimab) given along with standard chemoradiation for advanced cervical cancer. The goal is to see if adding this drug improves treatment effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have cervical cancer that is stage IIB, III, or IVA, and it has not spread to distant organs.
- You have not had surgery to remove the uterus, radiation, or chemotherapy for your cervical cancer before.
- You have at least one tumor that can be measured on a scan.
- Your overall health is good (able to do most daily activities) and your organs (like blood, liver, kidneys) work within normal limits.
- You are not pregnant and agree to use contraception if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemoradiation helps treat locally advanced cervical cancer better than chemoradiation alone.
This trial tests a new combination of short-course radiation, an immunotherapy drug called adebrelimab, and standard chemotherapy before surgery for locally advanced cervical cancer. It aims to see if this approach can shrink tumors more effectively.
This trial tests a drug called adebrelimab, given before and after standard treatment for locally advanced cervical cancer. The goal is to see if adding this immunotherapy can shrink the tumor and improve outcomes.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.